Drug discovery centres join forces
Enlarge image


Drug discovery centres join forces

22.01.2013 - Four European top-notch translational health research centres have joined an alliance to accelerate global drug development.

The Global Alliance of Leading Drug Discovery and Development Centres, which pools the expertise of renowned drug development service centres, has the ambitious goal to ultimately improve the rate at which academic research is translated into new medicines. However, the centres are no white spots on the map: the founding organisations include the Canadian Centre for Drug Research and Development (CDRD); the Lead Discovery Center (LDC), Germany; the Scripps Research Institute, La Jolla (US); the Centre for Drug Design and Discovery (CD3), KU Leuven, Belgium; as well as UK-based MRC Technology and Cancer Research Technology.  

Dr. Bert Klebl, Managing Director and Chief Scientific Officer of the Lead Discovery Centre stressed, “By joining forces and sharing complementary expertise and infrastructure, we will be even more effective in closing the gap between basic research and industry to the benefit of patients.” The centres said they represent close to 400 drug developers collaborating with tens of thousands of academic scientists around the globe on more than 165 therapeutic projects. The alliance wants to establish itself as partner for the biopharmaceutical industry.  

Under the terms of the collaboration agreement, member organisations will collaborate on mutually-beneficial projects, share best practices, expertise and resources, and develop common standards and performance measurements - ultimately working together to improve the conversion of global early-stage technology into much needed therapies. Karimah Es Sabar, President and CEO of CDRD commented, “We see a multitude of translational research initiatives around the world, but until now, these have for the most part, worked in isolation of one another. This Alliance will be a powerful vehicle in bringing such organisations together, leveraging one another's strengths, and ultimately making for a much more effective global translational research environment.”


Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


17.09.2015 Another European biotech is coming with a hefty price tag for its US buyer. Amgen Inc. has acquired privatly held Dutch company Dezima Pharma B.V. for US$1.55bn (€1.37bn).


15.09.2015 German Merck’s biopharma business Merck Serono has laid the cornerstone for its newest R&D facility. The laboratory represents an investment of €65m.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • NEOVACS (F)0.75 EUR8.70%
  • THROMBOGENICS (B)4.16 EUR8.33%


  • BAVARIAN NORDIC (D)35.60 EUR-8.48%
  • IMMUPHARMA (UK)37.00 GBP-6.92%


  • CHRONTECH PHARMA (S)0.36 SEK3500.0%
  • THROMBOGENICS (B)4.16 EUR48.0%
  • ZEALAND PHARMA (DK)153.00 DKK26.4%


  • TRANSGENE (F)2.80 EUR-43.2%
  • GALAPAGOS (B)39.16 EUR-23.0%


  • KARO BIO (S)44.10 SEK5150.0%
  • CHRONTECH PHARMA (S)0.36 SEK414.3%
  • GALAPAGOS (B)39.16 EUR236.7%


  • NEOVACS (F)0.75 EUR-76.7%
  • BIOTEST (D)18.80 EUR-75.4%

No liability assumed, Date: 06.10.2015